Treatment of Patients with Inflammation of the Eyelids and Conjunctiva: Clinical Experience

Conjunctivitis and blepharoconjunctivitis are common pathologies in the structure of inflammatory eye diseases. The article describes the experience of treating inflammation of the eyelids and conjunctiva of infectious and allergic etiology in an outpatient setting. Under the supervision of ophthalmologists, there were 64 patients with the above diagnoses, the treatment regimen of which included modern topical drugs, depending on the etiology and severity of inflammation. In accordance with the clinical recommendations developed by the Russian Association of Ophthalmologists, the following groups of drugs are recommended for use: antibacterial, antiseptic, antihistamines, glucocorticosteroids, non-steroidal anti-inflammatory. In the treatment of infectious blepharoconjunctivitis, a combined drug containing an antibacterial drug (tobramycin) and a corticosteroid (dexamethasone) — Rubrodex was successfully used. 0.05% moxifloxacin (Xaflom ®) eye drops have shown high efficacy, safety and good tolerability in the treatment of bacterial conjunctivitis in the context of an observed increase in antibiotic resistance of etiologically significant microflora. In relieving the symptoms of seasonal allergic blepharoconjunctivitis, efficacy and safety were demonstrated by the use of a new generation of dual-mechanism antihistamines epinastin 0.05% (Epinepta ®).

1. Trubilin VN, Poluninа EG, Kozhukhov AA, Kurenkov VV, Moreva NV, Trubilin AV. Medical therapy for conjunctivitis. Literature review. The EYE GLAZ. 2023;25(3):225–233 (In Russ.). doi: 10.33791/2222‑4408‑2023‑3‑225‑233.

2. Babushkin AE. Local antibiotic therapy of bacterial infections and inflammatory diseases of the anterior segment of the eye (literature review). Point of view. EastWest. 2021;2:89–93. doi: 10.25276/2410‑1257‑2021‑2‑89‑93.

3. Prygunova G.N. Results of using Signicef (Levofloxacin 0.5%, eye drops) in the treatment of bacterial conjunctivitis. Modern technologies in ophthalmology. 2016;2: 223‑225.

4. Azari AA, Barney NP. Conjunctivitis: a systematic review of diagnosis and treatment. JAMA. 2013;310(16):1721–1729. doi: 10.1001/jama.2013.280318.

5. Brzhesky VV. Allergic conjunctivitis: a guide for the outpatient ophthalmologist. RMJ. Medical Review. 2018;1(II):74–79 (In Russ.).

6. Yani EV. Using a new antiallergic drug Epinepta® in the treatment of seasonal allergic conjunctivitis. Clinical cases. Russian ophthalmological journal. 2023;16(4):141– 146 (In Russ.). doi: 10.21516/2072‑0076‑2023‑16‑4‑141‑146.

7. Vorontsova TN, Prozornaya LP. Treatment of bacterial conjunctivitis in children. Оphthalmology in Russia. 2014;11(4):87–93 (In Russ.). doi: 10.18008/1816‑50952014‑4‑87‑93.

8. Maychuk Yu.F., Pozdnyakova V.V., Seliverstova K.E. Levofloxacin in a new dosage form of eye drops. Cataract and Refractive Surgery. 2011; 11(3):54‑56.

9. Marnych SA, Evsegneeva IV. Oftaquix for the treatment of bacterial and chlamydial conjunctivitis. Refractive surgery and ophthalmology. 2009;9(2):50–54 (In Russ.).

10. Saidasheva EI, Buyanovskaya SV, Kovshov FV, Gudimova IV, Fanta EA, Chetvernya LN, Dubok NP. The application of modern fluoroquinilones for the treatment of bacterial eye infections in the young children. Russian Pediatric Ophthalmology . 2015;10(1):22–25 (In Russ.).

11. Astakhov SYu, Vokhmyakov AV. Ophthalmic fluoroquinolones in the treatment and prevention of eye infections. Clinical ophthalmology. 2008;9(1):28–30 (In Russ.).

12. Katz DV. Cipromed in the treatment of infectious eye diseases.Russian Journal of Clinical Ophthalmology. 2007;8(3):128–130 (In Russ.).

13. Danilov AI, Zharkova LP. Antimicrobial resistance: arguments and facts. Clin. Pharmacol. Ther. 2017;26(5):6–9 (In Russ.).

14. Seppala H, Al‑Juhaish M, Jarvinen H. Effect of prophylactic antibiotics on antimicrobial resistance of viridans streptococci in the normal fl ora of cataract surgery patients. J. Cataract. Refract. Surg. 2004;30(2):307–315.

15. Recchia FM, Busbee BG, Pearlman RB., Carvalho‑Recchia CA, Ho AC.. Changing trends in the microbiologic aspects of postcataract endophthalmitis. Arch. Ophthalmol. 2005;123(3):341–346. doi: 10.1001/archopht.123.3.341.

16. Namazova‑Baranova LS, Baranov AA. Antibiotic resistance in modern world. Pediatric pharmacology. 2017;14(5):341–354 (In Russ.). doi: 10.15690/pf.v14i5.1782.

17. Samuylo EK. Antimicrobial resistance among bacterial pathogens causing ocular infections in Russia. Clinical microbiology and antimicrobial chemotherapy. 2013;15(2):106–114.

18. Azamatova GA, Gaysina GYa. Study of antibiotic sensitivity of the most prevalent pathogens of postoperative inflammatory infectious complications in ophthalmic surgery. Bulletin of the Bashkir State Medical University. 2014;2:47–52.

19. Gaysina GYa. Susceptibility of most frequent pathogens of infectious postoperative inflammatory complications in ophthalmic surgery to modern topical antibiotics. Bashkortostan medical journal. 2015;10(1):83–86.

20. Abelson MB, Gomes P, Crampton HJ, Schiffman RM, Bradford RR, Whitcup SM. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther. 2004;26(1):35–47. doi: 10.1016/s0149‑2918(04)90004‑59‑2025‑25‑1‑8.

21. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs. 2005;65(2):215–228. doi: 10.2165/00003495‑200565020‑00004.

22. Azamatova GA, Altynbaeva GR. Treatment of patients with allergic conjunctivitis: experience of an outpatient ophthalmologist. Russian Journal of Clinical Ophthalmology. 2025;25(1):54–59 (In Russ.). doi: 10.32364/2311‑7729‑2025‑25‑1‑8.